Involvement of both cholinergic and catecholaminergic pathways in the central action of methylphenidate

A study utilizing lead-exposed rats

Tsung Ming Shih, Zaven S. Khachaturian, Israel Hanin

Research output: Contribution to journalArticle

Abstract

The effects of methylphenidate (MPH) and the cholinergic agonists nicotine and oxotremorine were tested on the spontaneous multiple unit activity in the mesencephalic reticular formation of two groups of rats. In control rats i.v. MPH (1 mg/kg), nicotine (0.125 mg/kg), and oxotremorine (0.5 mg/kg) all attenuated the unit activity with latencies of less than 10 min. In another group of rats, exposed to lead acetate since birth, the extent of attenuation of unit activity induced by MPH and nicotine was reduced and the latency of effect was delayed by 45-50 min. The latency of the oxotremorine effect was not changed but the attenuation of unit activity was more pronounced in the lead-treated group. Pretreatment with spiroperidol, to inhibit the aminergic receptors, diminished the inhibitory effect of MPH in the control group but not in the lead-treated group, whereas the attenuating effect of oxotremorine was not affected in either group. These data support our previous evidence that MPH exerts its action in the central nervous system by a cholinergic pathway in addition to published catecholaminergic pathways. Furthermore, the present findings indicate that chronic leadexposure in rats results in cholinergic hypofunction and supersensitivity at central cholinergic receptor sites. This alteration of central cholinergic function may be partially attributed to the malnutrition observed in the lead-exposed animals.

Original languageEnglish (US)
Pages (from-to)187-193
Number of pages7
JournalPsychopharmacology
Volume55
Issue number2
DOIs
StatePublished - Jun 1977
Externally publishedYes

Fingerprint

Methylphenidate
Oxotremorine
Cholinergic Agents
Nicotine
Spiperone
Cholinergic Agonists
Cholinergic Receptors
Malnutrition
Central Nervous System
Lead
Parturition
Control Groups

Keywords

  • Cholinergic and catecholaminergic effects
  • CNS
  • Hyperkinesis
  • Lead toxicity
  • Mesencephalic reticular formation
  • Methylphenidate
  • Model
  • Nicotine
  • Oxotremorine
  • Supersensitivity

ASJC Scopus subject areas

  • Pharmacology

Cite this

Involvement of both cholinergic and catecholaminergic pathways in the central action of methylphenidate : A study utilizing lead-exposed rats. / Shih, Tsung Ming; Khachaturian, Zaven S.; Hanin, Israel.

In: Psychopharmacology, Vol. 55, No. 2, 06.1977, p. 187-193.

Research output: Contribution to journalArticle

@article{033a8572da494e65961ca07fc7fe28b7,
title = "Involvement of both cholinergic and catecholaminergic pathways in the central action of methylphenidate: A study utilizing lead-exposed rats",
abstract = "The effects of methylphenidate (MPH) and the cholinergic agonists nicotine and oxotremorine were tested on the spontaneous multiple unit activity in the mesencephalic reticular formation of two groups of rats. In control rats i.v. MPH (1 mg/kg), nicotine (0.125 mg/kg), and oxotremorine (0.5 mg/kg) all attenuated the unit activity with latencies of less than 10 min. In another group of rats, exposed to lead acetate since birth, the extent of attenuation of unit activity induced by MPH and nicotine was reduced and the latency of effect was delayed by 45-50 min. The latency of the oxotremorine effect was not changed but the attenuation of unit activity was more pronounced in the lead-treated group. Pretreatment with spiroperidol, to inhibit the aminergic receptors, diminished the inhibitory effect of MPH in the control group but not in the lead-treated group, whereas the attenuating effect of oxotremorine was not affected in either group. These data support our previous evidence that MPH exerts its action in the central nervous system by a cholinergic pathway in addition to published catecholaminergic pathways. Furthermore, the present findings indicate that chronic leadexposure in rats results in cholinergic hypofunction and supersensitivity at central cholinergic receptor sites. This alteration of central cholinergic function may be partially attributed to the malnutrition observed in the lead-exposed animals.",
keywords = "Cholinergic and catecholaminergic effects, CNS, Hyperkinesis, Lead toxicity, Mesencephalic reticular formation, Methylphenidate, Model, Nicotine, Oxotremorine, Supersensitivity",
author = "Shih, {Tsung Ming} and Khachaturian, {Zaven S.} and Israel Hanin",
year = "1977",
month = "6",
doi = "10.1007/BF01457857",
language = "English (US)",
volume = "55",
pages = "187--193",
journal = "Psychopharmacology",
issn = "0033-3158",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Involvement of both cholinergic and catecholaminergic pathways in the central action of methylphenidate

T2 - A study utilizing lead-exposed rats

AU - Shih, Tsung Ming

AU - Khachaturian, Zaven S.

AU - Hanin, Israel

PY - 1977/6

Y1 - 1977/6

N2 - The effects of methylphenidate (MPH) and the cholinergic agonists nicotine and oxotremorine were tested on the spontaneous multiple unit activity in the mesencephalic reticular formation of two groups of rats. In control rats i.v. MPH (1 mg/kg), nicotine (0.125 mg/kg), and oxotremorine (0.5 mg/kg) all attenuated the unit activity with latencies of less than 10 min. In another group of rats, exposed to lead acetate since birth, the extent of attenuation of unit activity induced by MPH and nicotine was reduced and the latency of effect was delayed by 45-50 min. The latency of the oxotremorine effect was not changed but the attenuation of unit activity was more pronounced in the lead-treated group. Pretreatment with spiroperidol, to inhibit the aminergic receptors, diminished the inhibitory effect of MPH in the control group but not in the lead-treated group, whereas the attenuating effect of oxotremorine was not affected in either group. These data support our previous evidence that MPH exerts its action in the central nervous system by a cholinergic pathway in addition to published catecholaminergic pathways. Furthermore, the present findings indicate that chronic leadexposure in rats results in cholinergic hypofunction and supersensitivity at central cholinergic receptor sites. This alteration of central cholinergic function may be partially attributed to the malnutrition observed in the lead-exposed animals.

AB - The effects of methylphenidate (MPH) and the cholinergic agonists nicotine and oxotremorine were tested on the spontaneous multiple unit activity in the mesencephalic reticular formation of two groups of rats. In control rats i.v. MPH (1 mg/kg), nicotine (0.125 mg/kg), and oxotremorine (0.5 mg/kg) all attenuated the unit activity with latencies of less than 10 min. In another group of rats, exposed to lead acetate since birth, the extent of attenuation of unit activity induced by MPH and nicotine was reduced and the latency of effect was delayed by 45-50 min. The latency of the oxotremorine effect was not changed but the attenuation of unit activity was more pronounced in the lead-treated group. Pretreatment with spiroperidol, to inhibit the aminergic receptors, diminished the inhibitory effect of MPH in the control group but not in the lead-treated group, whereas the attenuating effect of oxotremorine was not affected in either group. These data support our previous evidence that MPH exerts its action in the central nervous system by a cholinergic pathway in addition to published catecholaminergic pathways. Furthermore, the present findings indicate that chronic leadexposure in rats results in cholinergic hypofunction and supersensitivity at central cholinergic receptor sites. This alteration of central cholinergic function may be partially attributed to the malnutrition observed in the lead-exposed animals.

KW - Cholinergic and catecholaminergic effects

KW - CNS

KW - Hyperkinesis

KW - Lead toxicity

KW - Mesencephalic reticular formation

KW - Methylphenidate

KW - Model

KW - Nicotine

KW - Oxotremorine

KW - Supersensitivity

UR - http://www.scopus.com/inward/record.url?scp=0017739036&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017739036&partnerID=8YFLogxK

U2 - 10.1007/BF01457857

DO - 10.1007/BF01457857

M3 - Article

VL - 55

SP - 187

EP - 193

JO - Psychopharmacology

JF - Psychopharmacology

SN - 0033-3158

IS - 2

ER -